⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074979 | 0.78 | — | — | |
| SCHEMBL11025043 | 0.76 | — | — | |
| SCHEMBL17761097 | 0.76 | — | — | |
| SCHEMBL13778233 | 0.76 | — | — | |
| SCHEMBL22372039 | 0.71 | CYP1A2 (0.45) | — | |
| SCHEMBL24059154 | 0.71 | — | — | |
| SCHEMBL4741241 | 0.71 | — | — | |
| SCHEMBL26605418 | 0.71 | — | — | |
| SCHEMBL22372059 | 0.67 | GABRG2 (0.41) | — | |
| SCHEMBL22372065 | 0.67 | CA12 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4269400-B1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE SA (PL) | 2025-07-09 | — | — | EP | claimed |
| EP-3740481-B9 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-10-23 | — | — | EP | claimed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | claimed |
| EP-3740481-B1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-06-26 | — | — | EP | claimed |
| EP-4192464-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Origenis GmbH (DE) | 2023-06-14 | — | — | EP | claimed |
| WO-2022011337-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | claimed |
| WO-2022011338-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | claimed |
| EP-3837252-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4536664-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-01 | — | — | US | disclosed |
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| CN-101883760-A | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMA | 2010-11-10 | — | — | CN | disclosed |
| EP-2227453-A2 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009049180-A2 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
| WO-2008130321-A2 | NOVEL N-TETRAHYDRONAPHTALENE OR 5-HETEROCYCLYL-CHROMANE OR 8-HETEROCYCLYL-TETRAHYDRONAPHTALENE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| CN-1620294-A | Pyrimidine A2BSelective antagonist compounds, their synthesis and use | OSI PHARM INC (US) | 2005-05-25 | — | — | CN | disclosed |